Form 4: Elevation Oncology Director R Michael Carruthers Granted 35,000 Stock Options

Elevation Oncology, Inc. director R Michael Carruthers was granted 35,000 stock options with an exercise price of $0.3051, vesting fully in one year.

Summary

• R Michael Carruthers, a Director of Elevation Oncology, Inc. (ELEV), was granted 35,000 stock options.
• The transaction date for this grant was June 5, 2025.
• The exercise price for these stock options is $0.3051 per share.
• The options vest 100% on the one-year anniversary of the grant date, subject to Mr. Carruthers' continued service to the Issuer.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, R Michael Carruthers beneficially owns 35,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with shareholders, incentivizing long-term performance. It is a routine compensation practice, indicating stability rather than significant new developments.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedule encourages the director's continued service and commitment to the company.

Future Outlook

The granted stock options are set to vest 100% on the one-year anniversary of the grant date, contingent upon the director's continued service to Elevation Oncology, Inc.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align management and board interests with shareholder value.

Related Party Transactions

• The grant of 35,000 stock options to R Michael Carruthers, a Director of Elevation Oncology, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such compensation practices can set precedents for incentive structures within the company.

Next Steps

• The stock options will vest on June 5, 2026, provided the reporting person continues to provide service to the Issuer.

Key Dates

Keywords

Elevation Oncology, ELEV, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Biotechnology, Pharmaceuticals